Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-30

Clinical Trial Update: Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 study evaluated valganciclovir dosing in pediatric solid organ transplant recipients to prevent CMV infection; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Valcyte (valganciclovir)

Snippet

Sponsor: Rabin Medical Center | Conditions: Infection in Solid Organ Transplant Recipients | Phase 4 | Status: COMPLETED | Results posted: 2016-06-30